Uncategorized

ZYDUS CADILA SEEKS APPROVAL FROM DRUG CONTROLLER GENERAL OF INDIA FOR THE USE OF HEPATITIS C TO TREAT COVID-19 PATIENTS

Zydus Cadila has announced that it was seeking approval from Drug Controller General of India (DCGI) for the use of its proprietary Hepatitis C drug as a treatment against the SARS-CoV-2 infection following promising results in Phase 3 trials.

According to the Zydus Statement, the Phase 3 trials demonstrated that a higher proportion of patients in the PegIFN arm showed a two point statistically significant clinical improvement on Day 8 as compared to the SOC arm (80.36% vs 68.18%).

Discussing the latest findings, Dr Sharvil Patel, MD at Cadila Healthcare, said, “We are encouraged by the results of Phase III study of Pegylated Interferon alpha 2b which has confirmed the potential to reduce virus titres when given earlier in the disease. With Indian Innovation at the forefront helping the country fight the pandemic with diagnostics, vaccines and therapeutics, this marks an important milestone. At Zydus, we stand committed to our endeavour of supporting patients and caregivers with access to treatment options that are affordable and can help in better disease management of Covid-19 at different stages.”

 

The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies